Advanced search
Publication Cover
Current Medical Research and Opinion Volume 22, 2006 - Issue 1
Submit an article Journal homepage
441
Views
41
CrossRef citations to date
0
Altmetric
Original Article

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology

Jacques Touchon CHU, INSERM 361, Montpellier, FranceCorrespondence[email protected]
,
Howard Bergman McGill University/Jewish General Hospital, Montreal, Quebec, Canada
,
Roger Bullock Kingshill Research Centre, Swindon, UK
,
Günter Rapatz Novartis Pharma AG, Basel, Switzerland
,
Jennifer Nagel Novartis Pharma AG, Basel, Switzerland
&
Roger Lane Novartis Pharmaceuticals, East Hanover, NJ, USA
Pages 49-59 | Accepted 31 Oct 2005, Published online: 15 Nov 2005

Citations (41)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Michael Shanks, Miia Kivipelto, Roger Bullock & Roger Lane. (2009) Cholinesterase inhibition: is there evidence for disease-modifying effects?. Current Medical Research and Opinion 25:10, pages 2439-2446.
Read now
Richard A Hansen, Gerald Gartlehner, Aaron P Webb, Laura C Morgan, Charity G Moore & Daniel E Jonas. (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis. Clinical Interventions in Aging 3:2, pages 211-225.
Read now
Ramón Cacabelos. (2007) Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiatric Disease and Treatment 3:3, pages 303-333.
Read now
Rawan Tarawneh & James E Galvin. (2007) Distinguishing Lewy body dementias from Alzheimer’s disease. Expert Review of Neurotherapeutics 7:11, pages 1499-1516.
Read now
Ben Seltzer. (2007) Donepezil: an update. Expert Opinion on Pharmacotherapy 8:7, pages 1011-1023.
Read now

Articles from other publishers (36)

Federico Emanuele Pozzi, Elisa Conti, Ildebrando Appollonio, Carlo Ferrarese & Lucio Tremolizzo. (2022) Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review. Frontiers in Neuroscience 16.
Crossref
Mehmet Koca, Uğur Güller, Pınar Güller, Ziya Dağalan & Bilal Nişancı. (2022) Design and Synthesis of Novel Dual Cholinesterase Inhibitors: In Vitro Inhibition Studies Supported with Molecular Docking . Chemistry & Biodiversity 19:6.
Crossref
Oday Halhouli, Qiang Zhang & Georgina M. Aldridge. 2022. Cognition in Parkinson's Disease. Cognition in Parkinson's Disease 407 434 .
Ketil Oppedal, Daniel Ferreira, Lena Cavallin, Afina W. Lemstra, Mara Kate, Alessandro Padovani, Irena Rektorova, Laura Bonanni, Lars‐Olof Wahlund, Knut Engedal, Flavio Nobili, Milica Kramberger, John‐Paul Taylor, Jakub Hort, Jon Snædal, Frederic Blanc, Zuzana Walker, Angelo Antonini, Eric Westman & Dag Aarsland. (2018) A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. Alzheimer's & Dementia 15:3, pages 400-409.
Crossref
Cristóbal de los Ríos & José Marco-Contelles. (2019) Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines. European Journal of Medicinal Chemistry 166, pages 381-389.
Crossref
Humberto Foyaca Sibat & Lourdes de Fatima Ibanez Valdes. 2019. Cognitive Disorders. Cognitive Disorders.
Ankur Butala, Melissa Shepard & Greg Pontone. 2019. Psychopharmacology of Neurologic Disease. Psychopharmacology of Neurologic Disease 83 121 .
Jacqueline S Birks & Richard J Harvey. (2018) Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2018:6.
Crossref
Huey Kwong, Siau Mah, Tze Chia, Ching Quah, Gin Lim & C. Kumar. (2017) Cholinesterase Inhibitory Activities of Adamantyl-Based Derivatives and Their Molecular Docking Studies. Molecules 22:6, pages 1005.
Crossref
Mercedes Unzeta, Gerard Esteban, Irene Bolea, Wieslawa A. Fogel, Rona R. Ramsay, Moussa B. H. Youdim, Keith F. Tipton & José Marco-Contelles. (2016) Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease. Frontiers in Neuroscience 10.
Crossref
Kimberly A. Madson & Sherrill Brown. (2016) Rivastigmine: Dementia with Lewy Bodies. Hospital Pharmacy 51:2, pages 129-131.
Crossref
Farzana Pervin, Carolyn Edwards & Carol F. Lippa. (2015) Dementia With Lew Body. American Journal of Alzheimer's Disease & Other Dementiasr 31:1, pages 5-17.
Crossref
Jacqueline S Birks, Lee-Yee Chong & John Grimley Evans. (2015) Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews.
Crossref
Jacqueline S Birks & John Grimley Evans. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Omar Mukhtar & Stephen HD Jackson. (2015) Drug therapies in older adults (part 1). Clinical Medicine 15:1, pages 47-53.
Crossref
Jennifer G. Goldman, Caroline Williams-Gray, Roger A. Barker, John E. Duda & James E. Galvin. (2014) The spectrum of cognitive impairment in Lewy body diseases. Movement Disorders 29:5, pages 608-621.
Crossref
T. Lebouvier, J. Delrieu, S. Evain, A. Pallardy, A. Sauvaget, F. Letournel, R. Chevrier, M. Lepetit, M. Vercelletto, C. Boutoleau-Bretonnière & P. Derkinderen. (2013) Démences : où sont les corps de Lewy ?. Revue Neurologique 169:11, pages 844-857.
Crossref
John E. Morley. (2013) Dementia With Lewy Bodies: A Common Condition in Nursing Homes?. Journal of the American Medical Directors Association 14:10, pages 713-714.
Crossref
Stella Karantzoulis & James E. Galvin. (2013) Update on Dementia with Lewy Bodies. Current Translational Geriatrics and Experimental Gerontology Reports 2:3, pages 196-204.
Crossref
Katalin Kupai, Gergely Banoczi, Gabor Hornyanszky, Pal Kolonits & Lajos Novak. (2012) Facile synthesis of cycloalkanoindole derivatives by aza-Claisen rearrangement. Monatshefte für Chemie - Chemical Monthly 143:12, pages 1663-1669.
Crossref
Antonio Cherubini, Carmelinda Ruggiero, Giuseppina Dell'Aquila, Paolo Eusebi, Beatrice Gasperini, Elisa Zengarini, Annarita Cerenzia, Giovanni Zuliani, Antonio Guaita & Fabrizia Lattanzio. (2012) Underrecognition and Undertreatment of Dementia in Italian Nursing Homes. Journal of the American Medical Directors Association 13:8, pages 759.e7-759.e13.
Crossref
Michal Rolinski, Chris Fox, Ian Maidment & Rupert McShane. (2012) Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews 2014:7.
Crossref
Yoko Furukawa-Hibi, Tursun Alkam, Atsumi Nitta, Akihiro Matsuyama, Hiroyuki Mizoguchi, Kazuhiko Suzuki, Saliha Moussaoui, Qian-Sheng Yu, Nigel H. Greig, Taku Nagai & Kiyofumi Yamada. (2011) Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. Behavioural Brain Research 225:1, pages 222-229.
Crossref
Jason A. Bailey & Debomoy K. Lahiri. (2010) A novel effect of rivastigmine on pre‐synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s disease. Journal of Neurochemistry 112:4, pages 843-853.
Crossref
Robert C Young, Herbert C Schulberg, Ariel G Gildengers, Martha Sajatovic, Benoit H Mulsant, Laszlo Gyulai, John Beyer, Lauren Marangell, Mark Kunik, Thomas Ten Have, Martha L Bruce, Ruben Gur, Patricia Marino, Jovier D Evans, Charles F Reynolds III & George S Alexopoulos. (2010) Conceptual and methodological issues in designing a randomized, controlled treatment trial for geriatric bipolar disorder: GERI‐BD. Bipolar Disorders 12:1, pages 56-67.
Crossref
Steven Ferris, Agneta Nordberg, Hilkka Soininen, Taher Darreh-Shori & Roger Lane. (2009) Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenetics and Genomics 19:8, pages 635-646.
Crossref
Roger M. Lane & Yunsheng He. (2009) Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE ε4, and hyperhomocysteinemia in neurodegenerative dementias. Medical Hypotheses 73:2, pages 230-250.
Crossref
Jacqueline Birks, John Grimley Evans, Vasso Iakovidou & Magda Tsolaki. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Robert Perneczky, Peter Häussermann, Alexander Drzezga, Henning Boecker, Oliver Granert, Regina Feurer, Hans Förstl & Alexander Kurz. (2009) Fluoro-Deoxy-Glucose Positron Emission Tomography Correlates of Impaired Activities of Daily Living in Dementia With Lewy Bodies: Implications for Cognitive Reserve. The American Journal of Geriatric Psychiatry 17:3, pages 188-195.
Crossref
Benjamin Lam, Elizabeth Hollingdrake, James L Kennedy, Sandra E Black & Mario Masellis. (2009) Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Human Genomics 4:2, pages 91.
Crossref
Wolfgang Oertel, Werner Poewe, Erik Wolters, Peter Paul De Deyn, Murat Emre, Courtney Kirsch, Chuanchieh Hsu, Sibel Tekin & Roger Lane. (2008) Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson’s Disease Dementia. Drug Safety 31:1, pages 79-94.
Crossref
Elise Rowan, Ian G. McKeith, Brian K. Saxby, John T. O’Brien, David Burn, Urs Mosimann, Jane Newby, Sarah Daniel, Jonathan Sanders & Keith Wesnes. (2007) Effects of Donepezil on Central Processing Speed and Attentional Measures in Parkinson’s Disease with Dementia and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders 23:3, pages 161-167.
Crossref
Karen Ritchie & Florence Portet. (2006) ‘I think therefore I am’: improving cognition. Current Opinion in Psychiatry 19:6, pages 570-574.
Crossref
N. Chastan & A. Hartmann. (2006) Prise en charge médicale des patients atteints de syndromes parkinsoniens atypiques dégénératifs. Revue Neurologique 162:11, pages 1147-1158.
Crossref
. (2006) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 21:8, pages 803-810.
Crossref
Serge Gauthier, Bruno Vellas, Martin Farlow & David Burn. (2006) Aggressive course of disease in dementia. Alzheimer's & Dementia 2:3, pages 210-217.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.